Travere Therapeutics
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $224,563 | $169,584 | $127,199 | $129,689 |
Gross Profit | 167,410 | 100,433 | 127,136 | |
EBITDA | -68,105 | -28,633 | -9,210 | -632 |
EBIT | -32,867 | -34,422 | -18,769 | |
Net Income | -52,337 | -34,797 | -37,102 | 2,729 |
Net Change In Cash | 224,563 | 169,584 | 127,199 | 129,689 |
Free Cash Flow | 96,882 | 58,071 | -62,544 | 41,814 |
Cash | 123,542 | 117,735 | 78,362 | 93,035 |
Basic Shares | 94,627 | 93,479 | 91,868 | 90,293 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $490,728 | $233,175 | $145,238 | $109,460 |
Gross Profit | 480,389 | 225,431 | 133,788 | 105,040 |
EBITDA | 22,218 | -265,773 | -326,246 | -299,422 |
EBIT | -38,525 | -309,328 | -364,776 | -320,141 |
Net Income | -25,546 | -321,545 | -111,399 | -278,482 |
Net Change In Cash | 490,728 | 233,175 | 145,238 | 109,460 |
Cost of Revenue | -101,271 | |||
Free Cash Flow | -20,373 | -338,687 | -321,612 | -214,657 |
Cash | 93,035 | 58,535 | 58,176 | 61,688 |
Basic Shares | 89,211 | 78,889 | 74,267 | 63,758 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | -$0.55 |
2026-06-30 | -$0.37 |
2026-03-31 | $0.05 |
2025-12-31 | $0.37 |